Demonstrating strategies for initiation of insulin therapy: Matching the right insulin to the right patient

International Journal of Clinical Practice

Volumn 62, Issue 8, 2008, Pages 1255-1264

  Meneghini, L ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLIMEPIRIDE; GLIPIZIDE PLUS METFORMIN; GLUCOSE; INSULIN; INSULIN ASPART; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN LISPRO; ISOPHANE INSULIN; LONG ACTING INSULIN; METFORMIN; ROSIGLITAZONE;

ADD ON THERAPY; B LYMPHOCYTE; CLINICAL TRIAL; DIABETIC PATIENT; DISEASE COURSE; DRUG DELIVERY SYSTEM; DRUG DOSE INCREASE; DRUG DOSE REGIMEN; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG FORMULATION; DRUG WITHDRAWAL; GASTROINTESTINAL SYMPTOM; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; PRIORITY JOURNAL; REVIEW;

AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; INSULIN INFUSION SYSTEMS; INSULIN, ISOPHANE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 47149087514     PISSN: 13685031     EISSN: 17421241     Source Type: Journal    
DOI: 10.1111/j.1742-1241.2008.01816.x     Document Type: Review

References (51)

1. Centers for Disease Control. National Diabetes Fact Sheet. United States, 2005: General Information. http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf (accessed March 2007).
2. Wright A, Burden AC, Paisey RB et al. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Diabetes Care 2002 25 : 330 6.
3. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 352 : 837 53.
4. Stratton IM, Adler AI, Neil HA et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 321 : 405 12.
5. DCCT/EDIC Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 353 : 2643 53.
6. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2007 30 (Suppl. 1 S4 41.
7. American Association of Clinical Endocrinologists. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus. Endocr Pract 2007 13 : 4 68.
8. Jellinger PS, Davidson JA, Blonde L et al. Road maps to achieve glycemic control in type 2 diabetes mellitus: ACE/AACE Diabetes Road Map Task Force. Endocr Pract 2007 13 : 260 8.
9. Mayfield JA, White RD. Insulin therapy for type 2 diabetes: rescue, augmentation, and replacement of beta-cell function. Am Fam Physician 2004 70 : 489 500.
10. Palumbo PJ. The case for insulin treatment early in type 2 diabetes. Cleve Clin J Med 2004 71 : 385 2.
11. Comparison of Insulins. http://www.pharmacistsletter.com under "Useful Charts" (accessed September 2007).
12. Thomson PDR. Physicians' Desk Reference ®. Montvale, NJ : Thomson PDR, 2007.
13. Bethel MA, Feinglos MN. Basal insulin therapy in type 2 diabetes. J Am Board Fam Pract 2005 18 : 199 204.
14. Stoneking K. Initiating basal insulin therapy in patients with type 2 diabetes mellitus. Am J Health Syst Pharm 2005 62 : 510 8.
15. Bott S, Tusek C, Jacobsen LV et al. Insulin detemir under steady-state conditions: no accumulation and constant metabolic effect over time with twice daily administration in subjects with type 1 diabetes. Diabet Med 2006 23 : 522 8.
16. Heise T, Nosek L, Ronn BB et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004 53 : 1614 20.
17. Klein O, Lynge J, Endahl L et al. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. Diabetes Obes Metab 2007 9 : 290 9.
18. Heinemann L, Linkeschova R, Rave K et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000 23 : 644 9.
19. Lepore M, Pampanelli S, Fanelli C et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000 49 : 2142 8.
20. Guerci B, Sauvanet JP. Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes Metab 2005 31 : 4S7 24.
21. Philis-Tsimikas A, Charpentier G, Clauson P et al. Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes. Clin Ther 2006 28 : 1569 81.
22. Standl E, Maxeiner S, Raptis S. Once-daily insulin glargine administration in the morning compared to bedtime in combination with morning glimepiride in patients with type 2 diabetes: an assessment of treatment flexibility. Horm Metab Res 2006 38 : 172 7.
23. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care 2003 26 : 3080 6.
24. Hermansen K, Davies M, Derezinski T et al. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes. Diabetes Care 2006 29 : 1269 74.
25. Meneghini LF, Rosenberg KH, Koenen C et al. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. Diabetes Obes Metab 2007 9 : 418 27.
26. Schreiber SA, Haak T. Insulin glargine benefits patients with type 2 diabetes inadequately controlled on oral antidiabetic treatment: an observational study of everyday practice in 12,216 patients. Diabetes Obes Metab 2007 9 : 31 8.
27. Davies M, Storms F, Shutler S et al. Improvement of glycemic control in subjects with poorly controlled type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care 2005 28 : 1282 8.
28. Selam JL, Koenen C, Weng W et al. Improving glycemic control with insulin detemir using the 303 algorithm in insulin naive patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. Curr Med Res Opin 2008 24 : 11 20.
29. Meneghini L, Koenen C, Weng W et al. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes - results of the randomized, controlled PREDICTIVE™ 303 study. Diabetes Obes Metab 2007 9 : 902 13.
30. McSorley PT, Bell PM, Jacobsen LV et al. Twice-daily biphasic insulin aspart 30 versus biphasic human insulin 30: a double-blind crossover study in adults with type 2 diabetes mellitus. Clin Ther 2002 24 : 530 9.
31. Koivisto VA, Tuominen JA, Ebeling P. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients. Diabetes Care 1999 22 : 459 62.
32. Garber AJ. Premixed insulin analogues for the treatment of diabetes mellitus. Drugs 2006 66 : 31 49.
33. Rolla AR, Rakel RE. Practical approaches to insulin therapy for type 2 diabetes mellitus with premixed insulin analogues. Clin Ther 2005 27 : 1113 25.
34. Leiter LA, Ceriello A, Davidson JA et al. Postprandial glucose regulation: new data and new implications. Clin Ther 2005 27 (Suppl. B S42 56.
35. Boehm BO, Home PD, Behrend C et al. Premixed insulin aspart 30 vs. premixed human insulin 30/70 twice daily: a randomized trial in type 1 and type 2 diabetic patients. Diabet Med 2002 19 : 393 9.
36. Schwartz S, Zagar AJ, Althouse SK et al. A single-center, randomized, double-blind, three-way crossover study examining postchallenge glucose responses to human insulin 70/30 and insulin lispro fixed mixtures 75/25 and 50/50 in patients with type 2 diabetes mellitus. Clin Ther 2006 28 : 1649 57.
37. Malone JK, Kerr LF, Campaigne BN et al. Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy. Clin Ther 2004 26 : 2034 44.
38. Raskin P, Allen E, Hollander P et al. Initiating insulin therapy in type 2 diabetes: a comparison of biphasic and basal insulin analogs. Diabetes Care 2005 28 : 260 5.
39. Lingvay I, Kaloyanova PF, ms-Huet B et al. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. J Investig Med 2007 55 : 62 8.
40. Hirsch IB, Bergenstal RM, Parkin CG et al. A real-world approach to insulin therapy in primary care practice. Clin Diabetes 2005 23 : 78 86.
41. Garber AJ, Wahlen J, Wahl T et al. Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing with biphasic insulin aspart 70/30 (the 1-2-3 study). Diabetes Obes Metab 2006 8 : 58 66.
42. Ligthelm RJ, Mouritzen U, Lynggaard H et al. Biphasic insulin aspart given thrice daily is as efficacious as a basal-bolus insulin regimen with four daily injections. Exp Clin Endocrinol Diabetes 2006 114 : 511 9.
43. Rosenstock J, Ahmann AJ, Colon G et al. Advancing insulin therapy in type 2 diabetes, previously treated with Glargine plus oral agents: prandial premixed (Lispro/ILPS) vs. basal/bolus (Glargine/Lispro) therapy. Diabetes Care 2008 31 : 20 5.
44. Nathan DM, Buse JB, Davidson MB et al. Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2006 29 : 1963 72.
45. Haak T, Tiengo A, Draeger E et al. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes. Diabetes Obes Metab 2005 7 : 56 64.
46. Raslova K, Tamer SC, Clauson P et al. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. Clin Drug Invest 2007 27 : 279 85.
47. Fonseca V, Bell DS, Berger S et al. A comparison of bedtime insulin glargine with bedtime neutral protamine Hagedorn insulin in patients with type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am J Med Sci 2004 328 : 274 80.
48. Siegmund T, Weber S, Blankenfeld H et al. Comparison of insulin glargine versus NPH insulin in people with type 2 diabetes mellitus under outpatient-clinic conditions for 18 months using a basal-bolus regimen with a rapid-acting insulin analogue as mealtime insulin. Exp Clin Endocrinol Diabetes 2007 115 : 349 53.
49. Meece J. Dispelling myths and removing barriers about insulin in type 2 diabetes. Diabetes Educ 2006 32 : 9S 18S.
50. Hirsch IB. Insulin analogues. N Engl J Med 2005 352 : 174 83.
51. Korytkowski M, Bell D, Jacobsen C et al. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther 2003 25 : 2836 48.